1. Home
  2. HROW vs PWP Comparison

HROW vs PWP Comparison

Compare HROW & PWP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HROW
  • PWP
  • Stock Information
  • Founded
  • HROW 1998
  • PWP 2006
  • Country
  • HROW United States
  • PWP United States
  • Employees
  • HROW N/A
  • PWP N/A
  • Industry
  • HROW Biotechnology: Pharmaceutical Preparations
  • PWP Finance: Consumer Services
  • Sector
  • HROW Health Care
  • PWP Finance
  • Exchange
  • HROW Nasdaq
  • PWP Nasdaq
  • Market Cap
  • HROW 1.4B
  • PWP 1.3B
  • IPO Year
  • HROW N/A
  • PWP N/A
  • Fundamental
  • Price
  • HROW $45.09
  • PWP $23.06
  • Analyst Decision
  • HROW Strong Buy
  • PWP Hold
  • Analyst Count
  • HROW 7
  • PWP 3
  • Target Price
  • HROW $64.67
  • PWP $23.67
  • AVG Volume (30 Days)
  • HROW 506.9K
  • PWP 1.1M
  • Earning Date
  • HROW 11-12-2025
  • PWP 11-07-2025
  • Dividend Yield
  • HROW N/A
  • PWP 1.24%
  • EPS Growth
  • HROW N/A
  • PWP N/A
  • EPS
  • HROW N/A
  • PWP 0.90
  • Revenue
  • HROW $227,661,000.00
  • PWP $871,012,000.00
  • Revenue This Year
  • HROW $45.86
  • PWP $1.99
  • Revenue Next Year
  • HROW $41.41
  • PWP $25.18
  • P/E Ratio
  • HROW N/A
  • PWP $25.08
  • Revenue Growth
  • HROW 47.69
  • PWP 20.01
  • 52 Week Low
  • HROW $20.85
  • PWP $14.12
  • 52 Week High
  • HROW $59.23
  • PWP $27.03
  • Technical
  • Relative Strength Index (RSI)
  • HROW 74.17
  • PWP 59.58
  • Support Level
  • HROW $42.23
  • PWP $21.56
  • Resistance Level
  • HROW $44.07
  • PWP $22.75
  • Average True Range (ATR)
  • HROW 1.76
  • PWP 0.84
  • MACD
  • HROW 0.52
  • PWP 0.01
  • Stochastic Oscillator
  • HROW 98.28
  • PWP 89.88

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.

About PWP Perella Weinberg Partners

Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.

Share on Social Networks: